Early detection can be a lifeline for newborns at risk of seizures, and NeuroBell is building technology to make that a reality. The company, which develops novel products for the monitoring of neonatal seizures, has just closed a Series A funding round, securing $5.5M.
This fresh capital will advance NeuroBell's work in facilitating better treatment and improving patient outcomes for the most vulnerable infants.















